… The key deliverables for “ProQR Vision 2023” include: Sepofarsen (formerly QR-110) for Leber's congenital amaurosis … Officer at ProQR. “Clinical data for our lead program, sepofarsen, has presented strong potential for this medicine …
… investigator of the ProQR Phase 1/2 clinical trial of sepofarsen and Chairman and Head of the Department of … PhD, co-investigator of the PQ-110-001 clinical trial of sepofarsen and Research Professor of Ophthalmology at the …
Senior leader with extensive global rare disease commercialization experience
Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022
… Western world have LCA10 because of this mutation. About SepofarsenSepofarsen (QR-110) is being evaluated in the pivotal Phase … splicing of the mRNA and non-functional CEP290 protein. Sepofarsen is designed to enable normal splicing, resulting …
… targets in H2 2022 Company plans to discuss findings from sepofarsen Illuminate trial with regulators and provide an … have LCA10 because of this mutation. About s epofarsen Sepofarsen (QR-110) is an investigational RNA therapy …
… we continue to analyze data from the Illuminate trial of sepofarsen and identify next steps for the program, if any,” … as solid – ProQR has deep RNA expertise, a pipeline beyond sepofarsen, an exciting RNA-editing platform, and a strong …
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinicAccelerated development of Axiomer™ for CNS ap